Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Safety and Efficacy of Oral Etrasimod in Adult Participants With Eosinophilic Esophagitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have an eosinophilic esophagitis (EoE) diagnosis prior to screening and histologically active disease with an esophageal peak eosinophil count (PEC) of ≥ 15 eosinophils per high powered field (eos/hpf)~* Have dysphagia, defined as solid food going down slowly or getting stuck in the throat with an average frequency of ≥ 2 episodes per week over 2 weeks during the Screening period~Inclusion Criteria for the Extension Treatment Period~* Completion of the Week 24 study visit \[including esophagogastroduodenoscopy (EGD)\]~* Compliance with study procedures during the Double-Blind Treatment Period as assessed by the Investigator~* No notable safety concerns during the Double-Blind Treatment Period, as determined by the Investigator~* Willing to comply with all study visits and procedures for the Extension Treatment Period~Exclusion Criteria:~* History of any of the non-EoE conditions or procedures that may interfere with the evaluation of or affect the histologic (eg eosinophilic gastritis), endoscopic (eg, high-grade esophageal stenosis), or symptom endpoints (eg, esophageal resection) of the study~* Undergone dilation of an esophageal stricture within 12 weeks prior to Screening EGD~* Use of corticosteroids for the treatment of EoE within 8 weeks prior to Screening EGD~* Discontinue, initiate, or change dosing (dosage/frequency) of the following therapies for EoE within 8 weeks prior to Screening EGD. Participants on any of the following therapy need to stay on a stable regimen during study participation:~  1. Elemental diet~ 2. EoE food trigger elimination diet~ 3. Proton pump inhibitor (PPI) therapy~* Used any immunotherapy/desensitization including oral immunotherapy (OIT) or sublingual immunotherapy (SLIT) within 12 months prior to the Screening EGD. Note: Stable (ie, ≥ 6 months prior to the Screening EGD) subcutaneous immunotherapy (SCIT) is permitted. Participants on SCIT need to stay on a stable treatment during study participation~* Used any protocol-specified immunomodulatory therapies within the protocol-specified timeframe prior to Baseline (eg, dupilumab, benralizumab, omalizumab, or infliximab within 12 weeks; a sphingosine-1-phosphate receptor modulator at any time)~* Use of any investigational agent or device within 12 weeks prior to Baseline~* Females who are pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Etrasimod Dose 1 (Type: EXPERIMENTAL): None
- Etrasimod Dose 2 (Type: EXPERIMENTAL): None
- Placebo and Etrasimod (Type: PLACEBO_COMPARATOR): Participants will receive etrasimod matching placebo tablet during the Double-Blind Treatment Period and etrasimod tablet during the Extension Treatment Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).